NOT ALL PAST SUCCESSES IN CANCER RESEARCH NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONSHAVE BEEN FOLLOWED BY ACTIONS

EUROCHIP-2EUROCHIP-2 THE ACTIONTHE ACTION Project & newsProject & news

Public Health ProgramEUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE - GENERAL

www.tumori.net/eurochip

WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?

• It is a translational research project (from epidemiology to public health)

• It is a project against disparities

• It is an EC project

• It aims to research ways to promote health by EU imprimatur

• Its goal is to promote public health actions against cancer in each EU country

• It works in the building of an European platform for cancer control

EUROPE WITHIN THE WORLDEUROPE WITHIN THE WORLDAGE-STANDARDIZED INCIDENCE RATES

Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000

EUROPE WITHIN THE WORLDEUROPE WITHIN THE WORLD

Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000

AGE-STANDARDIZED MORTALITY RATES

All cancers combined: Europe5-year age-adj. relative survival trend in male

8.5

7.5

10.5

6.7

12.1

6.6

8.9

8.8

6.3

7.9

9.2

8.7

4.5

7.2

5.2

3.5

6.6

-2.31.8

0 10 20 30 40 50 60

Iceland

Sweden

Swiss

Dutch

French

German

Norway

Finland

Spanish

Europe

Italian

English

Denmark

Wales

Scotland

Slovenia

Estonia

Slovakia

Polish

Relative survival

1984

1993-1984

8.0

6.5

5.2

9.5

6.4

4.5

4.7

7.4

7.5

7.5

6.4

3.9

4.5

4.0

6.8

7.3

6.3

3.9

0 10 20 30 40 50 60

French

Swiss

Sweden

Dutch

Spanish

German

Finland

Iceland

Norvay

Italian

Europe

English

Slovenia

Wales

Scotland

Slovakia

Estonia

Polish

Relative survival

1984

1993-1984

5-year age-adj. relative survival trend in female

Differences in Europe. Relative risks (Max/Min). All cancers combined

Year Males Females

Mortality1985 2.3 1.8

1996 4.3 1.9

Incidence1985 1.9 1.9

1996 1.9 2.2

5-yrs Survival1985-89 2.2 2.0

1990-94 2.5 2.0

Sources: EUROCIM - EUROCARE

Data from cancer registries of these countries

Austria, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom

Disks are proportional to the national health expenditure ($ PPP)

$ PPP: Parity Purchasing Power per capita (US $) Sourcesi: OECD 2002 and EUROCARE-3

GDP (1997) and 5-year cancer survival

INDICATOR AINDICATOR BINDICATOR C...INDICATOR Z

INDICATOR AINDICATOR BINDICATOR C...INDICATOR Z

INFORMATION

ANALYSIS

ACTIONS

GENERAL AIMS OF EUROCHIP-2GENERAL AIMS OF EUROCHIP-2

1. To extend the collaboration

2. To promote national groups in each country

3. To analyse the behaviour of available indicators

4. To discuss on deficiencies at national and international level

5. To promote at least one important ACTION in each country

EUROCHIP-2: MAPEUROCHIP-2: MAP

EUROCHIP-2 DISCUSSION PLANEUROCHIP-2 DISCUSSION PLAN

COUNTRY 1 COUNTRY 2 COUNTRY 3 COUNTRY 30

ACTION 1

ACTION 2

ACTION 3

ACTION 3

ACTION 4

ACTION 4

ACTION 5

ACTION 6

ACTION 6

EUROPEAN PUBLIC HEALTH ACTION –

early diagnosis

Cervical screening

EUROPEAN PUBLIC HEALTH ACTION –

care & treatment

Pilot studies

EUROPEAN PUBLIC HEALTH ACTION -

prevention

Dietary prevention

EU CANCER PLAN

UTERUS CANCER STANDARDIZED MORTALITY RATEAGE: 20 – 44 (IN THESE AGES MOSTLY CERVICAL CANCER)

European standard per 100,000

htt

p:/

/ep

ica

nce

r.is

s.it

PILLA

R 1EARLY

DIAGNOSIS

- Describe the opportunistic/programmed cervical cancer screening in those countries at present time

- For countries without cervical screening programs: find difficulties and problems with specific assessment studies in these Eastern European countries

- For countries with cervical screening programs: to help specific activities that at the moment are not subsidize

- To create relations with groups of pressure with national health ministries and with European Parliament

- To share information with other networks (EUNICE, European Cancer Screening networks)

EUROCHIP-2 ACTION:TASK FORCE ON CERVICAL CANCER SCREENING

AIMSACTION 1

ASSESSMENT PHASES: ASSESSMENT PHASES: COLLECTION OF INFO ONCOLLECTION OF INFO ON

• Use of Policies, Guidelines, and Norms

• Program Management Issues

• Health Services

• Information and Education Activities

• Community Perspectives

• Laboratory

• Information Systems

ROMANIA

ROMANIA

Screening prices Screening prices VS VS

treatment pricestreatment prices• In Bulgaria the mean value of programme screening for 1

person is around 5 €

• Target population: 1.8 million (age 25-60)

• Screening interval: 3 years

• 5 € * 0.6 million = 3 million € per year

V.

Zla

tko

v -

Bu

lgar

ia (

2006

)

BULGARIA

BULGARIA

Cervical cancerstages

Number of cases in Bulgaria (2001)

Prices according to EU data(Andrae Bengt - 2004)

Per item Total

St. III – IV 347 30 000 € 10 410 000 €

St. I – II 670 9 000 € 6 030 000 €

CIS 275 300 € 83 500 €

Total 1292 - 16 522 500 €

BULGARIAN BULGARIAN ESTIMATESESTIMATES

ESTONIA

ESTONIA PROBLEMS OF THE ORGANISED PROBLEMS OF THE ORGANISED SCREENING PROGRAMSCREENING PROGRAM

P. Veerus - Estonia (2006)

• Low participation: Only 21.7% of the 12,960 invited women attended the screening

• No funds for screening registry

• No invitation of women without insurance (~5% of population)

• To use experience from other countries to produce successful campaigns

• Group of pressure for invitation of women without insurance

• Money for starting the organization of screening registry

EUROCHIP FUNDEUROCHIP FUND

1.Budget: 17.500 € - Only for personnel costs

2. Involvement of personnel for ACTIONS

3.Money sent:

• Directly to personnel OR

• To Institute involved in the project

4.Necessary admin. documentation (at the end of the work)

• Declaration of money receipt (by personnel)

• Declaration of personnel payment (by Institute)

EUROCHIP-2 FUNDS:THE ACTION IN LATVIA